SynAct PharmaSynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

January 11, 2021Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB
January 11, 2021Flaggningsmeddelande i SynAct Pharma AB
November 13, 2020Pressmeddelande, 13 november 2020 SynAct Pharma publicerar delårsrapport Q3 2020
November 9, 2020SynAct Pharma tillkännager positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication

Donation to Reumatikerförbundet

Calendar

February 12, 2021Bokslutskommuniké, 2020

Subscribe to our press releases